0RAM Stock Overview
Through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Vistin Pharma ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 24.30 |
| 52 Week High | NOK 27.60 |
| 52 Week Low | NOK 22.80 |
| Beta | 0.89 |
| 11 Month Change | -11.96% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 17.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RAM | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -12.0% | 4.4% | 1.7% |
| 1Y | n/a | 2.0% | 9.0% |
Return vs Industry: Insufficient data to determine how 0RAM performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0RAM performed against the UK Market.
Price Volatility
| 0RAM volatility | |
|---|---|
| 0RAM Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RAM's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0RAM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 75 | Magnus Tolleshaug | www.vistin.com |
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Vistin Pharma ASA Fundamentals Summary
| 0RAM fundamental statistics | |
|---|---|
| Market cap | NOK 1.04b |
| Earnings (TTM) | NOK 61.37m |
| Revenue (TTM) | NOK 426.52m |
17.0x
P/E Ratio2.4x
P/S RatioIs 0RAM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RAM income statement (TTM) | |
|---|---|
| Revenue | NOK 426.52m |
| Cost of Revenue | NOK 148.95m |
| Gross Profit | NOK 277.57m |
| Other Expenses | NOK 216.20m |
| Earnings | NOK 61.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.38 |
| Gross Margin | 65.08% |
| Net Profit Margin | 14.39% |
| Debt/Equity Ratio | 1.8% |
How did 0RAM perform over the long term?
See historical performance and comparison